vs
Side-by-side financial comparison of Organon & Co. (OGN) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $1.1B, roughly 1.4× PERRIGO Co plc). Organon & Co. runs the higher net margin — -13.6% vs -127.8%, a 114.2% gap on every dollar of revenue. On growth, PERRIGO Co plc posted the faster year-over-year revenue change (-2.5% vs -5.3%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $96.0M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -3.6%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
OGN vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.1B |
| Net Profit | $-205.0M | $-1.4B |
| Gross Margin | 49.2% | 32.6% |
| Operating Margin | -9.8% | -116.0% |
| Net Margin | -13.6% | -127.8% |
| Revenue YoY | -5.3% | -2.5% |
| Net Profit YoY | -288.1% | -3093.9% |
| EPS (diluted) | $-0.78 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $1.5B | $1.0B | ||
| Q4 24 | $1.6B | $1.1B | ||
| Q3 24 | $1.6B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B | ||
| Q1 24 | $1.6B | $1.1B |
| Q4 25 | $-205.0M | $-1.4B | ||
| Q3 25 | $160.0M | $7.5M | ||
| Q2 25 | $145.0M | $-8.4M | ||
| Q1 25 | $87.0M | $-6.4M | ||
| Q4 24 | $109.0M | $-44.4M | ||
| Q3 24 | $359.0M | $-21.0M | ||
| Q2 24 | $195.0M | $-108.4M | ||
| Q1 24 | $201.0M | $2.0M |
| Q4 25 | 49.2% | 32.6% | ||
| Q3 25 | 53.5% | 36.1% | ||
| Q2 25 | 54.8% | 34.4% | ||
| Q1 25 | 55.6% | 37.6% | ||
| Q4 24 | 56.3% | 33.9% | ||
| Q3 24 | 58.3% | 37.2% | ||
| Q2 24 | 58.4% | 37.0% | ||
| Q1 24 | 59.0% | 33.1% |
| Q4 25 | -9.8% | -116.0% | ||
| Q3 25 | 15.2% | 7.0% | ||
| Q2 25 | 14.4% | 4.3% | ||
| Q1 25 | 6.7% | 4.5% | ||
| Q4 24 | 8.1% | 10.0% | ||
| Q3 24 | 13.1% | 7.4% | ||
| Q2 24 | 14.6% | -2.5% | ||
| Q1 24 | 14.5% | -5.1% |
| Q4 25 | -13.6% | -127.8% | ||
| Q3 25 | 10.0% | 0.7% | ||
| Q2 25 | 9.1% | -0.8% | ||
| Q1 25 | 5.8% | -0.6% | ||
| Q4 24 | 6.8% | -3.9% | ||
| Q3 24 | 22.7% | -1.9% | ||
| Q2 24 | 12.1% | -10.2% | ||
| Q1 24 | 12.4% | 0.2% |
| Q4 25 | $-0.78 | $-10.23 | ||
| Q3 25 | $0.61 | $0.05 | ||
| Q2 25 | $0.56 | $-0.06 | ||
| Q1 25 | $0.33 | $-0.05 | ||
| Q4 24 | $0.42 | $-0.32 | ||
| Q3 24 | $1.38 | $-0.15 | ||
| Q2 24 | $0.75 | $-0.79 | ||
| Q1 24 | $0.78 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $574.0M | — |
| Total DebtLower is stronger | $8.6B | — |
| Stockholders' EquityBook value | $752.0M | $2.9B |
| Total Assets | $12.9B | $8.5B |
| Debt / EquityLower = less leverage | 11.49× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $574.0M | — | ||
| Q3 25 | $672.0M | $432.1M | ||
| Q2 25 | $599.0M | $454.2M | ||
| Q1 25 | $547.0M | $409.9M | ||
| Q4 24 | $675.0M | $558.8M | ||
| Q3 24 | $763.0M | $1.5B | ||
| Q2 24 | $704.0M | $542.8M | ||
| Q1 24 | $575.0M | $658.5M |
| Q4 25 | $8.6B | — | ||
| Q3 25 | $8.8B | — | ||
| Q2 25 | $8.9B | — | ||
| Q1 25 | $9.0B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $8.7B | — | ||
| Q2 24 | $8.7B | — | ||
| Q1 24 | $8.7B | — |
| Q4 25 | $752.0M | $2.9B | ||
| Q3 25 | $906.0M | $4.4B | ||
| Q2 25 | $733.0M | $4.5B | ||
| Q1 25 | $542.0M | $4.4B | ||
| Q4 24 | $472.0M | $4.3B | ||
| Q3 24 | $493.0M | $4.6B | ||
| Q2 24 | $144.0M | $4.5B | ||
| Q1 24 | $48.0M | $4.7B |
| Q4 25 | $12.9B | $8.5B | ||
| Q3 25 | $13.6B | $10.1B | ||
| Q2 25 | $13.5B | $10.1B | ||
| Q1 25 | $13.2B | $9.8B | ||
| Q4 24 | $13.1B | $9.6B | ||
| Q3 24 | $12.8B | $11.2B | ||
| Q2 24 | $12.2B | $10.4B | ||
| Q1 24 | $11.9B | $10.6B |
| Q4 25 | 11.49× | — | ||
| Q3 25 | 9.74× | — | ||
| Q2 25 | 12.14× | — | ||
| Q1 25 | 16.52× | — | ||
| Q4 24 | 18.81× | — | ||
| Q3 24 | 17.75× | — | ||
| Q2 24 | 60.11× | — | ||
| Q1 24 | 181.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $141.0M | $175.4M |
| Free Cash FlowOCF − Capex | $96.0M | $148.6M |
| FCF MarginFCF / Revenue | 6.4% | 13.4% |
| Capex IntensityCapex / Revenue | 3.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $538.0M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $141.0M | $175.4M | ||
| Q3 25 | $264.0M | $51.7M | ||
| Q2 25 | $220.0M | $75.9M | ||
| Q1 25 | $75.0M | $-64.5M | ||
| Q4 24 | $390.0M | $312.6M | ||
| Q3 24 | $141.0M | $42.2M | ||
| Q2 24 | $332.0M | $9.5M | ||
| Q1 24 | $76.0M | $-1.4M |
| Q4 25 | $96.0M | $148.6M | ||
| Q3 25 | $218.0M | $29.8M | ||
| Q2 25 | $181.0M | $56.7M | ||
| Q1 25 | $43.0M | $-90.0M | ||
| Q4 24 | $335.0M | $274.9M | ||
| Q3 24 | $99.0M | $15.1M | ||
| Q2 24 | $300.0M | $-18.9M | ||
| Q1 24 | $30.0M | $-26.5M |
| Q4 25 | 6.4% | 13.4% | ||
| Q3 25 | 13.6% | 2.9% | ||
| Q2 25 | 11.4% | 5.4% | ||
| Q1 25 | 2.8% | -8.6% | ||
| Q4 24 | 21.0% | 24.2% | ||
| Q3 24 | 6.3% | 1.4% | ||
| Q2 24 | 18.7% | -1.8% | ||
| Q1 24 | 1.8% | -2.4% |
| Q4 25 | 3.0% | 2.4% | ||
| Q3 25 | 2.9% | 2.1% | ||
| Q2 25 | 2.4% | 1.8% | ||
| Q1 25 | 2.1% | 2.4% | ||
| Q4 24 | 3.5% | 3.3% | ||
| Q3 24 | 2.7% | 2.5% | ||
| Q2 24 | 2.0% | 2.7% | ||
| Q1 24 | 2.8% | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | 1.65× | 6.89× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 1.70× | — | ||
| Q1 24 | 0.38× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OGN
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
